Hi, Folks,
Sure is quiet out here, considering the strange action with ESON of late. I've followed the company off and on, but have no position.
April 9th, the company warned it would miss estimates of .07, guiding analysts to .05. Three of them downgraded the stock, which got cut in half. When earnings actually came out on the 16th, they made the .07 number, after all. ESON has been buying a lot of their own stock of late, though I've not done the math to see if that's the reason they hit the #s. Insiders, including management (as opposed to directors) have also been nibbling.
Yet the stock remains near historic lows. Haven't done my due diligence yet, but this one looks like a screaming buy now. I suppose we're here because management lost some credibility with analysts as far as guidance is concerned. But management seems to be executing well, regulatory delays notwithstanding.
Is their IVUS stent technology being perceived as inferior? What am I missing? Anybody?
Cheers, Tuck |
